Across TCGA pan-cancer cohorts, DENND4B mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of DENND4B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DENND4B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DENND4B is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where DENND4B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DENND4B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.365	<.001	9	view →
LSCC	Male	All	−0.336	<.001	9	view →
HNSC	Male	III,IV	−0.145	.007	5	view →
COAD	Male	III,IV	−0.912	.010	3	view →
PDAC	Male	IV	−0.250	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: DENND4B RNA expression & survival · all DENND4B data types